Data of Italian Cancer Centers from two regions with high incidence of Sars CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19

Pala, Laura; Conforti, Fabio; Saponara, Maristella; De Pas, Tommaso; Giugliano, Federica; Salè, Emanuela Omodeo; Jemos, Costantino; Marco, Rubatto; Andrea, Agostini; Quaglino, Pietro; Fava, Paolo; Fierro, Maria Teresa; Queirolo, Paola

Background: Patients with cancer are presumed to have a higher risk to contract SARS-CoV-2 infection, because of their immunosuppressed status. The impact and course of COVID-19 infection in cancer patients receiving immunotherapy remains unknown. Objectives: To evaluate the safety of the management of patients with advanced melanoma treated with immunotherapy in two Cancer Centers located in areas of Italy with a high incidence of COVID-19 infections. Methods: We retrospectively analyzed data from January 1 to April 30, 2020 on patients with locally advanced and metastatic melanoma receiving immunotherapy at either Istituto Europeo di Oncologia (IEO) or Città della Salute e della Scienza University Hospital (CSSUH). Results: One-hundred and sixty nine patients with stage III and IV melanoma were treated with an immunotherapy regimen at either IEO or CSSUH. One-hundred and four patients continued treatment without interruption or delay, while 49 patients had a treatment delay. The main reasons for treatment delay were older age (median age of the group of patients with or without treatment-delay, respectively 60 and 69 years, p-value <0.001) and/or presence of comorbidities (percentage of patients with at least one comorbidity respectively 81% and 62%, in patients with or without treatment delay, p-value=0.001). One-hundred and twelve patients had at least one thoracic CT scan performed and radiological findings suspicious for COVID-19 were observed in only seven cases (4%). Fifteen patients (9%) developed symptoms potentially related to COVID-19; naso-pharingeal swabs were collected in nine patients and only one was positive for SARS-CoV-2. Conclusions The incidence of symptomatic COVID-19 infection observed in our cohort of patients with advanced malignant melanoma treated with immunotherapy appears meaningfully lower as compared with that reported in the overall population in Italy as well as in patients affected by solid tumors. We conclude that in patients with locally advanced and metastatic melanoma, immunotherapy can be safely continued without delay in the majority of cases, reserving precautionary delay only for the most frail patients.